Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Piper Jaffray Remains Sidelined on Endo Int'l (ENDP) Following 2Q Beat
August 9, 2016 8:59 AM EDTPiper Jaffray reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and raised the price target to $19.00 (from $18.00), following the company's 2Q earnings report. ENDP reported non-GAAP diluted EPS of $0.86 on revenue of $921M, compared to Street estimates of $0.74 and $864M, respectively.
Analyst David Amsellem commented, "Endo reported 2Q16... More
Endo Int'l (ENDP) Tops Q2 EPS by 12c, Affirms Guidance
August 8, 2016 4:32 PM EDTEndo Int'l (NASDAQ: ENDP) reported Q2 EPS of $0.86, $0.12 better than the analyst estimate of $0.74. Revenue for the quarter came in at $921 million versus the consensus estimate of $864.34 million.
Company affirms full year 2016 revenue and adjusted diluted EPS financial guidance.
Company expands management... More
